Based on the review data, it is hoped that it can be used as a reference regarding information of new potential bioactive compounds as an alternative treatment for fungal infections by their lanosterol 14 α demethylase CYP51 inhibition effect other than the use of antibiotics or currently used drugs. This evidence concerns the gene CYP51A1 and fungal infectious disease.